ABSI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABSI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Absci's PE Ratio without NRI is 0.00. Absci's 5-Year EBITDA growth rate is 0.00%. Therefore, Absci's PEG Ratio for today is N/A.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Absci's PEG Ratio or its related term are showing as below:
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
The historical data trend for Absci's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Absci Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
PEG Ratio | - | - | - | - | - |
Absci Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
PEG Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Absci's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Absci's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Absci's PEG Ratio falls into.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.
Absci's PEG Ratio for today is calculated as
PEG Ratio | = | PE Ratio without NRI | / | 5-Year EBITDA Growth Rate* |
= | / | 0.00 | ||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Absci (NAS:ABSI) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Thank you for viewing the detailed overview of Absci's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Frans Van Houten | director | 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683 |
Daniel A Rabinovitsj | director | 400 W CESAR CHAVEZ, AUSTIN TX 78701 |
Andreas Busch | director | C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
Sarah Korman | officer: General Counsel | 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98660 |
Todd Bedrick | officer: VP, CCPAO | 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683 |
Joseph Sirosh | director | C/O COMPASS, INC., 155 AVENUE OF THE AMERICAS, SIXTH FLOOR, NEW YORK NY 10013 |
Sean Mcclain | director, 10 percent owner, officer: President and Chief Executive | 18105 SE MILL PLAIN BLVD, SUITE 350, VANCOUVER WA 98683 |
Zachariah Jonasson | director | 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683 |
Eli Casdin | director, 10 percent owner | 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019 |
Casdin Partners Master Fund, L.p. | director, 10 percent owner | WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001 |
Redmile Group, Llc | director, 10 percent owner | ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
Karen K Mcginnis | director | INSIGHT ENTERPRISES INC, 1305 WEST AUTO DRIVE, TEMPE AZ 85284 |
Redmile Biopharma Investments Ii, L.p. | director, 10 percent owner | LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129 |
Phoenix General Partner Ii Llc | 10 percent owner | 1700 S. EL CAMINO REAL, SUITE 335, SAN MATEO CA 94402 |
Nikhil Goel | officer: Chief Business Officer | 101 E. 6TH STREET, SUITE 350, VANCOUVER WA 98660 |
From GuruFocus
By Marketwired • 07-26-2023
By Value_Insider Value_Insider • 11-02-2022
By Stock market mentor Stock market mentor • 02-08-2023
By sperokesalga sperokesalga • 03-23-2023
By Value_Insider Value_Insider • 11-23-2022
By Ds*** Ds*** • 09-01-2022
By Value_Insider Value_Insider • 10-26-2022
By sperokesalga sperokesalga • 06-15-2023
By Stock market mentor Stock market mentor • 01-10-2023
By sperokesalga sperokesalga • 02-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.